Topics

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

03:41 EDT 28 Oct 2019 | FinanzNachrichten

Lund Sweden, October 28 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and NeoTX announce that the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) ...

Original Article: Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

NEXT ARTICLE

More From BioPortfolio on "Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...